Information de reference pour ce titreAccession Number: | 00008390-201804000-00010.
|
Author: | Gallo, Susanna a; Coha, Valentina a; Caravelli, Daniela a; Becco, Paolo a,e; Venesio, Tiziana b; Zaccagna, Alessandro c; Giacone, Elena c; Marenco, Federica c; Pisacane, Alberto b; Racca, Manuela d; Gammaitoni, Loretta a; Aglietta, Massimo a,e; Carnevale-Schianca, Fabrizio a
|
Institution: | (a)Medical Oncology (b)Pathology Unit (c)Dermatology-Surgery Unit (d)Nuclear Medicine Unit, Candiolo Cancer Institute-FPO, IRCCS, Candiolo (e)Department of Oncology, University of Turin, Turin, Italy
|
Title: | |
Source: | Melanoma Research. 28(2):143-146, April 2018.
|
Abstract: | BRAF signaling is involved in melanoma growth in more than half of metastatic patients. In the last few years, new drugs that block this pathway have significantly improved the outcomes of patients with metastatic melanoma. Ninety percent of BRAF mutations involve exon 15, and the most frequent, V600E, results from the amino acid change from valine (V) to glutamic acid (E). BRAFV600 inhibitor treatments have shown a notable overall response rate and improvements in progression-free and overall survival. Rare BRAF mutations of codon 599 have been also described in a few patients with papillary thyroid cancer and melanoma. Nowadays, no evidence is available in the literature, describing the role of target therapies as treatment in patients with this specific codon mutation. We describe the case of a young woman with metastatic melanoma with a particular BRAF mutation, T599I, who has benefited from treatment with a BRAF inhibitor, vemurafenib.
Copyright (C) 2018 Wolters Kluwer Health, Inc. All rights reserved.
|
Author Keywords: | BRAF rare mutations; malignant melanoma; target therapy.
|
References: | 1. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al. Mutations of the BRAF gene in human cancer. Nature 2002; 417:949-954.
2. Goydos JS, Mann B, Kim HJ, Gabriel EM, Alsina J, Germino FJ, et al. Detection of B-RAF and N-RAS mutations in human melanoma. J Am Coll Surg 2005; 200:362-370.
3. Libra M, Malaponte G, Navolanic PM, Gangemi P, Bevelacqua V, Proietti L, et al. Analysis of BRAF mutation in primary and metastatic melanoma. Cell Cycle 2005; 4:1382-1384.
4. Flaherty KT, Puzanov I, Kim KB, Ribas A, McAthur GA, Soaman JA, et al. Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010; 363:809-819.
5. Sosman JA, Kim KB, Schuchter L, Gonzalez R, Pavlick AC, Weber JS, et al. Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib. N Engl J Med 2012; 366:707-714.
6. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med 2011; 364:2507-2516.
7. McArthur GA, Chapman PB, Robert C, Larkin J, Haanen JB, Dummer R, et al. Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. Lancet Oncol 2014; 15:323-332.
8. De Falco V, Giannini R, Tamburrino A, Ugolini C, Lupi C, Puxeddu E, et al. Functional characterization of the novel T599I-VKSRdel BRAF mutation in a follicular variant papillary thyroid carcinoma. J Clin Endocrinol Metab 2008; 93:4398-4402.
9. Chiosea S, Nikiforova M, Zuo H, Ogilvie J, Gandhi M, Seethala RR, et al. A novel complex BRAF mutation detected in a solid variant of papillary thyroid carcinoma. Endocr Pathol 2009; 20:122-126.
10. Zalaudek I, Ciarrocchi A, Piana S, Argenziano G, Torricelli F, Sancisi V, et al. A novel BRAF mutation in association with primary amelanotic melanoma with oral metastases. J Eur Acad Dermatol Venereol 2015; 29:387-390.
11. Wilson MA, Morrissette JJ, McGettigan S, Roth D, Elder, D, Schuchter LM, Daber RD. What you are missing could matter: a rare, complex BRAF mutation affecting codons 599, 600, and 601 uncovered by next generation sequencing. Cancer Genet 2014; 207:272-275.
12. Long GV, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F, Larkin J, et al. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial. Lancet 2015; 386:444-451.
13. Ascierto PA, McArthur GA, Dreno B, Atkinson V, Liszkay G, Di Giacomo AM, et al. Cobimetinib combined with vemurafenib in advanced BRAF(V600)-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial. Lancet Oncol 2016; 17:1248-1260.
14. Dahlman KB, Xia J, Hutchinson K, Ng C, Hucks D, Jia P, et al. BRAF(L597) mutations in melanoma are associated with sensitivity to MEK inhibitors. Cancer Discov 2012; 2:791-797.
15. Busser B, Leccia MT, Gras-Combe G, Bricault I, Templier I, Claeys A, et al. Identification of a novel complex BRAF mutation associated with major clinical response to vemurafenib in a patient with metastatic melanoma. JAMA Dermatol 2013; 149:1403-1406.
16. Trudel S, Odolczyk N, Dremaux J, Toffin J, Regnier A, Sevestre H, et al. The clinical response to vemurafenib in a patient with a rare BRAFV600DK601del mutation-positive melanoma. BMC Cancer 2014; 14:727.
17. Beadling C, Heinrich MC, Warrick A, Forbes EM, Nelson D, Justusson E, et al. Multiplex mutation screening by mass spectrometry evaluation of 820 cases from a personalized cancer medicine registry. J Mol Diagn 2011; 13:504-513.
18. Wan PT, Garnett MJ, Roe SM, Lee S, Niculescu-Duvaz D, Good VM, et al. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 2004; 116:855-867.
19. Shi H, Moriceau G, Kong X, Lee MK, Lee H, Koya RC, et al. Melanoma whole-exome sequencing identifies (V600E)B-RAF amplification-mediated acquired B-RAF inhibitor resistance. Nat Commun 2012; 3:724.
20. Wilmott JS, Tembe V, Howle JR, Sharma R, Thompson JF, Rizos H, et al. Intratumoral molecular heterogeneity in a BRAF-mutant, BRAF inhibitor-resistant melanoma: a case illustrating the challenges for personalized medicine. Mol Cancer Ther 2012; 11:2704-2708.
|
Language: | English.
|
Document Type: | SHORT COMMUNICATIONS.
|
Journal Subset: | Clinical Medicine.
|
ISSN: | 0960-8931
|
NLM Journal Code: | bjr, 9109623
|
DOI Number: | https://dx.doi.org/10.1097/CMR.0...- ouverture dans une nouvelle fenêtre
|
Annotation(s) | |
|
|